Genta Inc. (GETA.OB) Begins Phase 2 Trial of Tesetaxel
Today, Genta Inc. announced that the company has begun treatment of the first subject in a new Phase 2 trial of tesetaxel, used in relation to advanced melanoma. The study was initiated at the Anderson Cancer Center in Houston, TX, the lead center for Genta’s last two clinical trials in melanoma that have enrolled approximately 1,100 patients. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in development. Unlike its competition, the tesetaxel capsule can be taken orally. The study will examine the effects of tesetaxel in patients with advanced melanoma who have already been…